AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7628095 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant/albumin (S/A) ratios
Number of subjects: 47
Study 2038732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2038732 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (twice a day)
Number of subjects: 30
Study 2038732 — intervention group
Group type: COMPARATOR
Intervention: Inhaled terbutaline (1 mg four times a day)
Number of subjects: 30
Study 2038732 — intervention group
Group type: COMPARATOR
Intervention: Combination of theophylline and terbutaline
Number of subjects: 30
Study 2038732 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of terbutaline and theophylline
Number of subjects: 30
Study 2038732 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline
Number of subjects: 30
Study 2038732 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline alone
Number of subjects: 30
Study 30573851 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive Underfeeding
Number of subjects: 50
Study 30573851 — intervention group
Group type: COMPARATOR
Intervention: Standard Feeding
Number of subjects: 50
Study 27189615 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy made with chamomile infusion
Number of subjects: 38
Study 27189615 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy made only with water (control group)
Number of subjects: 38
Study 24666884 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine/pilocarpine (2/9 mg)
Number of subjects: 138
Study 24666884 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine IR 2 mg
Number of subjects: 138
Study 24666884 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 138
Study 24666884 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine/pilocarpine (3/13.5 mg)
Number of subjects: 138
Study 24666884 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine extended-release 4 mg
Number of subjects: 138
Study 21963581 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin multifaceted safety program
Number of subjects: 2117
Study 21963581 — intervention group
Group type: EXPERIMENTAL
Intervention: Accidental tube/catheter removal multifaceted safety program
Number of subjects: 2117
Study 21963581 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulation multifaceted safety program
Number of subjects: 2117
Study 21963581 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 2117
Study 20234126 — intervention group
Group type: EXPERIMENTAL
Intervention: >2 h of physical activity per week
Number of subjects: 597
Study 20234126 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported health status as fair or poor
Number of subjects: 597
Study 20234126 — intervention group
Group type: EXPERIMENTAL
Intervention: Total lung capacity (every 10% increase)
Number of subjects: 597
Study 20234126 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported anxiety
Number of subjects: 597
Study 18629370 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (an angiotensin II type 1 receptor blocker)
Number of subjects: 0
Study 18629370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (standard therapy)
Number of subjects: 0
Study 18629370 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 0
Study 16020522 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training over 12 weeks in lung transplant recipients (LR)
Number of subjects: 24
Study 16020522 — intervention group
Group type: COMPARATOR
Intervention: Exercise training over 12 weeks in male controls (C)
Number of subjects: 24
Study 16020522 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline measurements in lung transplant recipients (LR)
Number of subjects: 24
Study 16020522 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training measurements in lung transplant recipients (LR)
Number of subjects: 24
Study 16020522 — intervention group
Group type: COMPARATOR
Intervention: Post-training measurements in male controls (C)
Number of subjects: 24
Study 12900341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) 0.625 mg/d for 3 months
Number of subjects: 0
Study 12900341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (CEE) 0.3125 mg/d for 3 months
Number of subjects: 0
Study 12900341 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 11036894 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit
Number of subjects: 457
Study 11036894 — intervention group
Group type: COMPARATOR
Intervention: Stroke team
Number of subjects: 457
Study 11036894 — intervention group
Group type: COMPARATOR
Intervention: Domiciliary care
Number of subjects: 457
Study 9833023 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-EKG-triggered lithotripsy
Number of subjects: 25
Study 9833023 — intervention group
Group type: COMPARATOR
Intervention: Triggered lithotripsy
Number of subjects: 25
Study 9833023 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-EKG-triggering lithotripsy
Number of subjects: 25
Study 1281259 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + porcine galanin (12.5 micrograms/min in 100 mL saline)
Number of subjects: 12
Study 1281259 — intervention group
Group type: COMPARATOR
Intervention: GHRH + saline (100 mL)
Number of subjects: 12
Study 1281259 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + galanin infusion
Number of subjects: 12
Study 1281259 — intervention group
Group type: COMPARATOR
Intervention: GHRH
Number of subjects: 12
Study 6744948 — intervention group
Group type: EXPERIMENTAL
Intervention: Econazole nitrate 1.0 percent cream once a day
Number of subjects: 126
Study 6744948 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 126
Study 31731677 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related product information
Number of subjects: 0
Study 31731677 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental-friendliness-related product information
Number of subjects: 0
Study 31731677 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of health and environmental messages
Number of subjects: 0
Study 28826166 — intervention group
Group type: EXPERIMENTAL
Intervention: Myofascial trigger therapy (MT) combined with Cellconnect Impulse vibrotreatment
Number of subjects: 0
Study 28826166 — intervention group
Group type: COMPARATOR
Intervention: Myofascial trigger therapy (MT)
Number of subjects: 0
Study 26650913 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin strut bare metal stenting in AF patients
Number of subjects: 783
Study 26650913 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin strut bare metal stenting in non-AF patients
Number of subjects: 783
Study 25317087 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) of 40 mm Hg for 20 minutes
Number of subjects: 24
Study 22715372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg/day
Number of subjects: 219
Study 22715372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 20651475 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation instruction
Number of subjects: 83
Study 20651475 — intervention group
Group type: COMPARATOR
Intervention: Group discussion
Number of subjects: 83
Study 17106839 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute psychiatric day-hospital treatment
Number of subjects: 191
Study 17106839 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 191
Study 16381143 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Process Training (APT)
Number of subjects: 24
Study 16381143 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 12214339 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA (15 mg/kg day)
Number of subjects: 59
Study 12214339 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 9790157 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20+/−10 mg/day) during luteal phase only and placebo during follicular phase (intermittent treatment)
Number of subjects: 69
Study 9790157 — intervention group
Group type: COMPARATOR
Intervention: Citalopram continuously at a constant dosage (20+/−10 mg/day) throughout the menstrual cycle (continuous treatment)
Number of subjects: 69
Study 9790157 — intervention group
Group type: COMPARATOR
Intervention: Citalopram continuously throughout the cycle at a lower dosage in the follicular phases (5 mg/day) than in the luteal phases (20+/−10 mg/day) (semi-intermittent treatment)
Number of subjects: 69
Study 9790157 — intervention group
Group type: COMPARATOR
Intervention: Placebo throughout the cycles
Number of subjects: 69
Study 7615287 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy (n = 11)
Number of subjects: 58
Study 7615287 — intervention group
Group type: COMPARATOR
Intervention: No therapy (n = 10)
Number of subjects: 58
Study 7615287 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic treatment (n = 13)
Number of subjects: 58
Study 7615287 — intervention group
Group type: EXPERIMENTAL
Intervention: No previous bacteriologically proved urinary tract infection (n = 24)
Number of subjects: 58
Study 2236690 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) for diagnosing active inflammatory bowel disease (IBD)
Number of subjects: 61
Study 877819 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotic povidone-iodine
Number of subjects: 0
Study 877819 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon catheters
Number of subjects: 0
Study 877819 — intervention group
Group type: EXPERIMENTAL
Intervention: Steel needles
Number of subjects: 0
Study 877819 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine venipuncture inspections every eight hours
Number of subjects: 0
Study 877819 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion site examination every eight hours
Number of subjects: 0
Study 877819 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion duration
Number of subjects: 0
Study 31644921 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based behavioral lifestyle intervention program (24 months)
Number of subjects: 480
Study 31644921 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 480
Study 28452404 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal lifestyle intervention
Number of subjects: 1867
Study 28452404 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1867
Study 25527487 — intervention group
Group type: EXPERIMENTAL
Intervention: HABIT‐ILE (10 days = 90 hours)
Number of subjects: 24
Study 25527487 — intervention group
Group type: EXPERIMENTAL
Intervention: HABIT‐ILE
Number of subjects: 24
Study 25527487 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 24
Study 23640589 — intervention group
Group type: COMPARATOR
Intervention: 70 ml concentrated beetroot juice (BR)
Number of subjects: 10
Study 23640589 — intervention group
Group type: COMPARATOR
Intervention: 140 ml concentrated beetroot juice (BR)
Number of subjects: 10
Study 23640589 — intervention group
Group type: COMPARATOR
Intervention: 280 ml concentrated beetroot juice (BR)
Number of subjects: 10
Study 21482029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbances at baseline
Number of subjects: 322
Study 21482029 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep disturbances at 1 month post-quit
Number of subjects: 322
Study 21482029 — intervention group
Group type: EXPERIMENTAL
Intervention: Drowsiness, insomnia, and sleep quality changes over time
Number of subjects: 322
Study 2704174 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 30, 50, 70 mg/d for 4 weeks
Number of subjects: 117
Study 2704174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 16631668 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia course
Number of subjects: 126
Study 16631668 — intervention group
Group type: COMPARATOR
Intervention: Print version
Number of subjects: 126
Study 12072597 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Papillary Balloon Dilation (EPBD)
Number of subjects: 140
Study 12072597 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (EST)
Number of subjects: 140
Study 10483698 — intervention group
Group type: EXPERIMENTAL
Intervention: Indian version (maternal positioning exercise)
Number of subjects: 109
Study 10483698 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (spontaneous version)
Number of subjects: 109
Study 9772612 — intervention group
Group type: EXPERIMENTAL
Intervention: Niaodujing (NDJ) treatment
Number of subjects: 105
Study 9772612 — intervention group
Group type: COMPARATOR
Intervention: Control group (aldehyde coated oxystarch)
Number of subjects: 105
Study 9772612 — intervention group
Group type: COMPARATOR
Intervention: Comparison between NDJ and control group
Number of subjects: 105
Study 1656827 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy (MACC: intravenous methotrexate, intravenous doxorubicin, intravenous cyclophosphamide, and oral lomustine) followed by thoracic radiotherapy
Number of subjects: 121
Study 1656827 — intervention group
Group type: COMPARATOR
Intervention: Thoracic radiation therapy alone (5000 cGy in 5 weeks with a 1000 cGy boost)
Number of subjects: 121
Study 1656827 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 121
Study 1656827 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy only
Number of subjects: 121
Study 1656827 — intervention group
Group type: COMPARATOR
Intervention: Thoracic radiation only
Number of subjects: 121
Study 1656827 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 121
Study 6408808 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfinpyrazone (Anturan) 800 mg/die
Number of subjects: 19
Study 6408808 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study 31381152 — intervention group
Group type: EXPERIMENTAL
Intervention: fosnetupitant 81 mg
Number of subjects: 594
Study 31381152 — intervention group
Group type: EXPERIMENTAL
Intervention: fosnetupitant 235 mg
Number of subjects: 594
Study 31381152 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 594
Study 28776431 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavior therapy with therapist support (n=20)
Number of subjects: 42
Study 28776431 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive-behavior therapy without therapist support (n=22)
Number of subjects: 42
Study 27838685 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized, spectrally altered classical music therapy
Number of subjects: 50
Study 27838685 — intervention group
Group type: COMPARATOR
Intervention: Unaltered classical music (Control)
Number of subjects: 50
Study 24390009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS) for 20 minutes daily during treatment
Number of subjects: 21
Study 24390009 — intervention group
Group type: COMPARATOR
Intervention: Control group without LIPUS treatment
Number of subjects: 21
Study 22646847 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (405 mg/4 weeks, 210 or 300 mg/2 weeks)
Number of subjects: 404
Study 22646847 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral olanzapine (10 ± 2.5 or 15 ± 2.5 mg/day)
Number of subjects: 404
Study 22646847 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (15 ± 5 mg/day)
Number of subjects: 404
Study 22646847 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine LAI
Number of subjects: 404
Study 22646847 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral olanzapine
Number of subjects: 404
Study 22646847 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol and placebo
Number of subjects: 404
Study 22646847 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 404
Study 19387396 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB supplementation (3 g/d)
Number of subjects: 22
Study 18088023 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sublingual immunotherapy with SLITone grass mix plus olive pollen extract for 6 months
Number of subjects: 105
Study 18088023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 15148271 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-depleted erythrocytes (LD)
Number of subjects: 496
Study 15148271 — intervention group
Group type: COMPARATOR
Intervention: Standard buffy coat-depleted erythrocytes (PC)
Number of subjects: 496
Study 11575872 — intervention group
Group type: EXPERIMENTAL
Intervention: LongoVital (LV)
Number of subjects: 52
Study 11575872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 10872623 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic lobectomy (VATS), n = 22 patients
Number of subjects: 44
Study 10872623 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy approach, n = 22 patients
Number of subjects: 44
Study 8584467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, specific exercise using firm pelvic stabilization to isolate and rehabilitate the lumbar spine musculature.
Number of subjects: 895
Study 8584467 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 895
Study 2802032 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiglossectomy and radical neck dissection
Number of subjects: 0
Study 2802032 — intervention group
Group type: COMPARATOR
Intervention: Hemiglossectomy alone
Number of subjects: 0
Study 2802032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor depth < 4 mm
Number of subjects: 0
Study 2802032 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor depth > 4 mm
Number of subjects: 0
Study 60633 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme for history-taking skills
Number of subjects: 0
Study 60633 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of a printed handout presenting a detailed scheme for taking histories
Number of subjects: 0
Study 31759804 — intervention group
Group type: EXPERIMENTAL
Intervention: FRESH behavioral intervention (2 home visits and 7 phone sessions)
Number of subjects: 300
Study 31759804 — intervention group
Group type: EXPERIMENTAL
Intervention: FRESH behavioral intervention
Number of subjects: 300
Study 31759804 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 300
Study 31324206 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tinidazole
Number of subjects: 125
Study 31324206 — intervention group
Group type: EXPERIMENTAL
Intervention: Penile topical metronidazole
Number of subjects: 125
Study 31324206 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clindamycin
Number of subjects: 125
Study 31324206 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical hydrogen peroxide
Number of subjects: 125
Study 31324206 — intervention group
Group type: COMPARATOR
Intervention: Immediate penile circumcision (control)
Number of subjects: 125
Study 28525569 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate
Number of subjects: 21
Study 28525569 — intervention group
Group type: COMPARATOR
Intervention: Modafinil
Number of subjects: 21
Study 28525569 — intervention group
Group type: COMPARATOR
Intervention: 3,4‐methylenedioxymethamphetamine
Number of subjects: 21
Study 25950723 — intervention group
Group type: EXPERIMENTAL
Intervention: EPAP nasal strip
Number of subjects: 219
Study 23988600 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Number of subjects: 732
Study 23988600 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal intervention
Number of subjects: 732
Study 23988600 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 732
Study 19850570 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (group A)
Number of subjects: 1308
Study 19850570 — intervention group
Group type: COMPARATOR
Intervention: Usual care (group B)
Number of subjects: 1308
Study 19850570 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 1308
Study 19909586 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose GnRH agonist (0.5 mg leuprolide acetate) administered subcutaneously on day 6 after ICSI
Number of subjects: 164
Study 19909586 — intervention group
Group type: COMPARATOR
Intervention: Standard luteal support (intravaginal 600 mg micronized progesterone) without GnRH agonist
Number of subjects: 164
Study 19909586 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose GnRH agonist
Number of subjects: 164
Study 19909586 — intervention group
Group type: COMPARATOR
Intervention: Standard luteal support
Number of subjects: 164
Study 16736388 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (VXR)
Number of subjects: 120
Study 16736388 — intervention group
Group type: COMPARATOR
Intervention: Conventional antidepressants (CA, mainly SSRIs)
Number of subjects: 120
Study 16736388 — intervention group
Group type: COMPARATOR
Intervention: Conventional antidepressants (CA)
Number of subjects: 120
Study 16035398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (200 mg/day)
Number of subjects: 0
Study 16035398 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (1200 mg/day)
Number of subjects: 0
Study 16035398 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide and Ibuprofen (both)
Number of subjects: 0
Study 11384793 — intervention group
Group type: COMPARATOR
Intervention: Placebo diet intervention, no house dust mite reduction (Group A)
Number of subjects: 616
Study 11384793 — intervention group
Group type: COMPARATOR
Intervention: Placebo diet intervention, active house dust mite reduction (Group B)
Number of subjects: 616
Study 11384793 — intervention group
Group type: EXPERIMENTAL
Intervention: Active diet intervention, no house dust mite reduction (Group C)
Number of subjects: 616
Study 11384793 — intervention group
Group type: EXPERIMENTAL
Intervention: Active diet intervention, active house dust mite reduction (Group D)
Number of subjects: 616
Study 9422014 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially randomised patient preference design
Number of subjects: 273
Study 9422014 — intervention group
Group type: COMPARATOR
Intervention: Conventional randomised controlled design
Number of subjects: 273